本帖最后由 老马 于 2012-1-13 21:20 编辑 # |6 V' X- h2 ~# ?7 M1 B
7 m. f( N1 Z# k' o( M& d* r爱必妥和阿瓦斯丁的比较
- M) d# o9 r1 x* B) F
2 k$ E: I8 H. z9 F
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
6 B) Q( l& U) u1 x
- P; t9 m+ i! ~) H
& h/ q" p4 h6 p9 u: e7 I
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/8 n& }) n$ q, K
==================================================
7 Q+ h% I( {' ]* r4 t/ J% ~( DOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)6 a N O8 F# H( b6 s6 \1 D
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
2 O* [4 F M7 d- o b/ ~Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
9 b5 ]1 G$ j' f: O: D$ D* a
|